Akrotome Imaging, Inc.
Advances in cancer diagnostics have enabled the detection of cancer at its earliest stages when the chances for successful intervention are highest. For many tumors, surgery offers the best option for a cure, with the potential to remove all cancer tissue from the patient (a complete resection). However, the full potential of surgery is not realized because, in many cases, it is difficult for surgeons to see where cancer tissue ends and healthy tissue begins. Akrotome (a combination of two Greek words that means cutting at the edge) is focused on the development of fluorescent molecular probe technologies that light up cancer, enabling clear and precise visualization of tumors, with emphasis on tumor margins, where the cancer is growing rapidly and where invasion into healthy tissue occurs. Akrotome provides surgeons with the visualization tools they need to guide them to achieve complete resection of cancer tissue.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Medical Equipment
- Market Focus:
- Nationally (across the country)
- Year Founded:
- 2008
About Us
Who We Are
Akrotome is a Delaware corporation, first incorporated late 2008; the current team has been in place since 2012.
Our Focus
We are dedicated to the clinical translation of cancer-targeted molecular probes into enhanced approaches for surgery and diagnostics, leading to improved outcomes and patient quality of life while positively impacting healthcare economics.
How We Are Different
Akrotome’s molecular probes were designed from the ground up with an emphasis on the real-world requirements of cancer surgeons and the clinical workflow in the Operating Room. The result is a family of probes that offer superior performance, economics, and flexibility to other molecular probes on market.
While other probes use a “one size fits all” approach that requires systemic administration of large doses of probe hours or even days before surgery, Akrotome’s probes can meet a surgeon’s preference for an individual surgery, supporting the following application methods:
- In vivo with topical administration
- In vivo with systemic administration
- Ex vivo with topical administration
In addition, Akrotome probes are quenched and do not activate until they encounter cancer, virtually eliminating the background fluorescence common with other probes.
This flexibility translates into real and quantifiable benefits, including: reduced regulatory risk and expense; faster time to market, and potential lower-per-use cost/enhanced profitability.